Insider Selling: Azita Saleki-Gerhardt Sells 10,473 Shares of AbbVie Stock (ABBV)
AbbVie (NASDAQ:ABBV) SVP Azita Saleki-Gerhardt sold 10,473 shares of AbbVie stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $45.84, for a total value of $480,082.32. Following the completion of the sale, the senior vice president now directly owns 66,703 shares in the company. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on ABBV shares. Analysts at Argus initiated coverage on shares of AbbVie (NASDAQ:ABBV) in a research note to investors on Monday, August 12th. They set a “buy” rating and a $52.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Jefferies Group raised their price target on shares of AbbVie (NASDAQ:ABBV) from $51.00 to $54.00 in a research note to investors on Monday, August 5th. They now have a “buy” rating on the stock. Finally, analysts at Morgan Joseph raised their price target on shares of AbbVie (NASDAQ:ABBV) from $41.00 to $46.00 in a research note to investors on Monday, July 29th. They now have a “neutral” rating on the stock.
Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $46.36.
AbbVie (NASDAQ:ABBV) traded up 0.67% during mid-day trading on Wednesday, hitting $47.92. 6,689,426 shares of the company’s stock traded hands. AbbVie has a 1-year low of $33.33 and a 1-year high of $48.00. The stock has a 50-day moving average of $44.13 and a 200-day moving average of $43.11. The company has a market cap of $75.974 billion and a price-to-earnings ratio of 14.63.
AbbVie (NASDAQ:ABBV) last posted its quarterly earnings results on Friday, July 26th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.13. The company had revenue of $4.69 billion for the quarter, compared to the consensus estimate of $4.54 billion. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Analysts expect that AbbVie will post $3.13 EPS for the current fiscal year.
AbbVie Inc (NASDAQ:ABBV) is a research-based pharmaceuticals company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.